Pozetaldogene ormesparvovec

奥米哌泽多基

Report date: 2023/12/29 11:51:40

Base Information

Drug NamePozetaldogene ormesparvovec
Drug Alias NameSBT-101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionGene transferenceABCD1 gene stimulants
TargetsATP Binding Cassette Subfamily D Member 1
Therapy Area/IndicationsAdrenoleukodystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSwanBio Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSwanBio Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsAdrenoleukodystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A